Genentech Inc Biologic Trastuzumab; Hyaluronidase-Oysk Receives Approval in US
Genentech Biologic Trastuzumab Receives Approval in US
Astra`s Enhertu breast cancer trial shows `unprecedented` results
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
Accord BioPharma, the US speciality division of Intas Pharmaceuticals, has secured approval from the US Food and Drug Administration (FDA) for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab).
AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself.
DURHAM, N.C., April 29, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug Administration (FDA) has approved HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
April 5 (Reuters) - The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo (4568.T), opens new tab and AstraZeneca's (AZN.L), opens new tab drug to treat patients with a type of solid tumor.
Daiichi Sankyo`s Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.